Results 11 to 20 of about 42,124 (246)
Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression. [PDF]
PLoS ONEDespite the high sensitivity of estrogen receptor positive (ER+) breast cancer to endocrine therapy, many patients have primary resistance or develop resistance to endocrine therapies.
Xinlei Li +6 more
doaj +2 more sources
PLoS ONE, 2014 Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, most breast tumors develop tamoxifen resistance and are eventually refractory to tamoxifen therapy.
Li Yin +4 more
doaj +2 more sources
Non-coding RNA-mediated mechanisms underlying tamoxifen resistance in breast cancer [PDF]
Discover OncologyTamoxifen remains a cornerstone therapy for estrogen receptor-positive (ER⁺) breast cancer; however, the emergence of drug resistance significantly limits its therapeutic success.
Mohammed Khaleel Jameel +7 more
doaj +2 more sources
Association of tamoxifen resistance and lipid reprogramming in breast cancer [PDF]
BMC Cancer, 2018 Background Tamoxifen treatment of estrogen receptor (ER)-positive breast cancer reduces mortality by 31%. However, over half of advanced ER-positive breast cancers are intrinsically resistant to tamoxifen and about 40% will acquire the resistance during ...
Susanne Hultsch +7 more
doaj +3 more sources
LINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1 [PDF]
Scientific ReportsAlthough tamoxifen is commonly utilized as adjuvant therapy for Estrogen Receptor alpha (ERα)-positive breast cancer patients, approximately 30–50% of individuals treated with tamoxifen experience relapse.
Hui Yuan +3 more
doaj +2 more sources
Anti-Cancer Drugs, 2004 We investigated whether it is possible to reduce anti-estrogen resistance using liposomally encapsulated tamoxifen in vivo. Small liposomal vesicles containing up to 5.1 mg tamoxifen/ml liposomal suspension, together with an alkylphospholipid to enhance the cellular uptake, were prepared and characterized.
Zeisig, Reiner +2 more
core +5 more sources
Sox2 promotes tamoxifen resistance in breast cancer cells [PDF]
EMBO Molecular Medicine, 2013 Development of resistance to therapy continues to be a serious clinical problem in breast cancer management. Cancer stem/progenitor cells have been shown to play roles in resistance to chemo‐ and radiotherapy.
Marco Piva +10 more
doaj +2 more sources
A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen [PDF]
International Journal of Breast Cancer, 2011 About two thirds of all human breast cancer cases are estrogen receptor positive. The drug of first choice for these patients is tamoxifen.
Renée de Leeuw +2 more
doaj +3 more sources
Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer [PDF]
Cells, 2019 Tamoxifen resistance is a major hurdle in the treatment of estrogen receptor (ER)-positive breast cancer. The mechanisms of tamoxifen resistance are not fully understood although several underlying molecular events have been suggested.
Angela Maselli +17 more
doaj +2 more sources
AFF3 upregulation mediates tamoxifen resistance in breast cancers
Journal of Experimental & Clinical Cancer Research, 2018 Background Although tamoxifen is a highly effective drug for treating estrogen receptor–positive (ER+) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resistance ...
Yawei Shi +7 more
doaj +2 more sources